{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:57:38Z","timestamp":1773363458410,"version":"3.50.1"},"reference-count":44,"publisher":"The Journal of Rheumatology","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>MicroRNA (miRNA) are small noncoding RNA that posttranscriptionally regulate gene expression and serve as potential mediators and markers of disease. Recently, plasma miR-24-3p and miR-125a-5p concentrations were shown to be elevated in rheumatoid arthritis (RA) and useful for RA diagnosis. We assessed the utility of 7 candidate plasma miRNA, selected for biological relevance, for RA diagnosis and use as markers of disease activity and subclinical atherosclerosis in RA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>The cross-sectional study included 168 patients with RA and 91 control subjects of similar age, race, and sex. Plasma concentrations of miR-15a-5p, miR-24-3p, miR-26a-5p, miR-125a-5p, miR-146a-5p, miR-155-5p, and miR-223-3p were measured by quantitative PCR. Utility of plasma miRNA concentrations for RA diagnosis was assessed by area under the receiver-operating characteristic curve (AUROC). Associations between plasma miRNA concentrations and RA disease activity and coronary artery calcium score were assessed by Spearman correlations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Plasma concentrations of miR-15a-5p, miR-24-3p, miR-26a-5p, miR-125a-5p, miR-146a-5p, miR-155-5p, and miR-223-3p were significantly increased in patients with RA. The highest AUROC for diagnosis of RA (AUROC = 0.725) was found in miR-24-3p, including among rheumatoid factor\u2013negative patients (AUROC = 0.772). Among all patients with RA, the combination of miR-24-3p, miR-26a-5p, and miR-125a-5p improved the model modestly (AUROC = 0.747). One miRNA, miR-155-5p, was weakly inversely associated with swollen joint count (p = 0.024), but no other miRNA were associated with disease activity or coronary artery calcium score.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>The combination of miR-24-3p, miR-26a-5p, and miR-125a-5p had the strongest diagnostic accuracy for RA. Candidate miRNA had little or no association with RA disease activity or subclinical atherosclerosis.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.150232","type":"journal-article","created":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T20:30:01Z","timestamp":1438461001000},"page":"1746-1751","source":"Crossref","is-referenced-by-count":55,"title":["Utility of Select Plasma MicroRNA for Disease and Cardiovascular Risk Assessment in Patients with Rheumatoid Arthritis"],"prefix":"10.3899","volume":"42","author":[{"given":"Michelle J.","family":"Ormseth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph F.","family":"Solus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kasey C.","family":"Vickers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette M.","family":"Oeser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Raggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Michael","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2015,8,1]]},"reference":[{"key":"2018112909351372000_42.10.1746.1","doi-asserted-by":"publisher","DOI":"10.1038\/nature07242"},{"key":"2018112909351372000_42.10.1746.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(04)00045-5"},{"key":"2018112909351372000_42.10.1746.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.01.002"},{"key":"2018112909351372000_42.10.1746.4","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1596"},{"key":"2018112909351372000_42.10.1746.5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003694"},{"key":"2018112909351372000_42.10.1746.6","doi-asserted-by":"publisher","DOI":"10.1038\/ncb2210"},{"key":"2018112909351372000_42.10.1746.7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1019055108"},{"key":"2018112909351372000_42.10.1746.8","doi-asserted-by":"publisher","DOI":"10.1186\/ar3013"},{"key":"2018112909351372000_42.10.1746.9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0804549105"},{"key":"2018112909351372000_42.10.1746.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-0172(95)80031-X"},{"key":"2018112909351372000_42.10.1746.11","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200106)44:6<1234::AID-ART213>3.0.CO;2-R"},{"key":"2018112909351372000_42.10.1746.12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506654102"},{"key":"2018112909351372000_42.10.1746.13","doi-asserted-by":"publisher","DOI":"10.1002\/art.24762"},{"key":"2018112909351372000_42.10.1746.14","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201243271"},{"key":"2018112909351372000_42.10.1746.15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1200312"},{"key":"2018112909351372000_42.10.1746.16","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-11-209"},{"key":"2018112909351372000_42.10.1746.17","doi-asserted-by":"crossref","first-page":"974648","DOI":"10.1155\/2012\/974648","article-title":"Cardiovascular risk in systemic autoimmune diseases: epigenetic mechanisms of immune regulatory functions","volume":"2012","author":"Lopez-Pedrera","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"2018112909351372000_42.10.1746.18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0069118"},{"key":"2018112909351372000_42.10.1746.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.30651"},{"key":"2018112909351372000_42.10.1746.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.01.050"},{"key":"2018112909351372000_42.10.1746.21","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-013-0322-z"},{"key":"2018112909351372000_42.10.1746.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.21288"},{"key":"2018112909351372000_42.10.1746.23","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"2018112909351372000_42.10.1746.24","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"2018112909351372000_42.10.1746.25","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.18.1837"},{"key":"2018112909351372000_42.10.1746.26","doi-asserted-by":"publisher","DOI":"10.1186\/ar2098"},{"key":"2018112909351372000_42.10.1746.27","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280883"},{"key":"2018112909351372000_42.10.1746.28","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(90)90282-T"},{"key":"2018112909351372000_42.10.1746.29","unstructured":"Shipley GL . The MIQE guidelines uncloaked. PCR troubleshooting and optimization: the essential guide; 2011. [Internet. Accessed June 18, 2015.] Available from: www.gene-quantification.com\/shipley-miqe-chapter-8-2011.pdf"},{"key":"2018112909351372000_42.10.1746.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2007.01.004"},{"key":"2018112909351372000_42.10.1746.31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202815"},{"key":"2018112909351372000_42.10.1746.32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-544692"},{"key":"2018112909351372000_42.10.1746.33","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2014.224238"},{"key":"2018112909351372000_42.10.1746.34","doi-asserted-by":"publisher","DOI":"10.1002\/art.37890"},{"key":"2018112909351372000_42.10.1746.35","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0555-z"},{"key":"2018112909351372000_42.10.1746.36","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.426866"},{"key":"2018112909351372000_42.10.1746.37","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.327031"},{"key":"2018112909351372000_42.10.1746.38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202203"},{"key":"2018112909351372000_42.10.1746.39","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32835d8385"},{"key":"2018112909351372000_42.10.1746.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2009.11.008"},{"key":"2018112909351372000_42.10.1746.41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1215767111"},{"key":"2018112909351372000_42.10.1746.42","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1038\/ncomms4292","article-title":"HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells","volume":"5","author":"Tabet","year":"2014","journal-title":"Nat Commun"},{"key":"2018112909351372000_42.10.1746.43","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2010.16"},{"key":"2018112909351372000_42.10.1746.44","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-013-0372-2"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.150232","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T13:59:52Z","timestamp":1543499992000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.150232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,1]]},"references-count":44,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2015,10,1]]},"published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.3899\/jrheum.150232"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.150232","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,1]]}}}